SCHEMBL2600738

SCHEMBL2600738

Cc1nc(C)nc(C(C)C)n1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12931233 0.97 HRH4 (0.30)
SCHEMBL11802553 0.82 HRH4 (0.34)
SCHEMBL7770550 0.81 HRH4 (0.44)
SCHEMBL18711476 0.81 ADORA2A (0.31)
SCHEMBL14123523 0.77 ALDH1A1 (0.30)
SCHEMBL14665020 0.77 HSD17B10 (0.37)
SCHEMBL15853593 0.77
SCHEMBL10246448 0.77 GAA (0.38)
SCHEMBL20381735 0.75
SCHEMBL92460 0.73

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240226114-A1 INHIBITORS AND USES THEREOF VIVIDION THERAPEUTICS, INC. 2024-07-11 US disclosed
US-20230292611-A1 ORGANIC ELECTROLUMINESCENT COMPOUND, A PLURALITY OF HOST MATERIALS, AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING THE SAME DUPONT SPECIALTY MATERIALS KOREA LTD. (KR) 2023-09-14 US disclosed
US-20220340577-A1 GCN2 INHIBITORS AND USES THEREOF VERTEX PHARMACEUTICALS INCORPORATED 2022-10-27 US disclosed
WO-2022115039-A1 MAGNETIC NANOCOMPOSITE MATERIALS SUITABLE FOR MAGNETIC LOCALIZED POLYMERISATION OF AN ANAEROBIC ADHESIVE NANYANG TECHNOLOGICAL UNIVERSITY (SG) 2022-06-02 WO disclosed
EP-3988120-A1 NHE3-BINDING COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT Ardelyx, Inc. (US) 2022-04-27 EP disclosed
EP-3590541-B1 DRUG-CONJUGATES AND USES THEREOF CONCORTIS BIOSYSTEMS CORP (US) 2021-08-11 EP disclosed
US-11018309-B2 Organic electroluminescent materials and devices UNIVERSAL DISPLAY CORPORATION (US) 2021-05-25 US disclosed
WO-2020243457-A1 COMPOUNDS AND THERAPEUTIC USES THEREOF VIOGEN BIOSCIENCES, LLC (US) 2020-12-03 WO disclosed
EP-3559136-B1 MASTIC ASPHALT COMPOSITION FOR PRODUCTION OF SURFACINGS TOTAL MARKETING SERVICES (FR) 2020-09-09 EP disclosed
US-RE46974-E1 Organic electroluminescence device IDEMITSU KOSAN CO., LTD. (JP) 2018-07-31 US disclosed
US-20120095022-A1 DERIVATIVES OF 10-AMINO-1,2,3,4-TETRAHYDROPYRIDO[2,1-A]ISOINDOL-6(10BH)-ONES, METHOD FOR PREPARATION THEREOF AND THERAPEUTIC USES THEREOF UNIVERSITE D'ORLEANS (FR) 2012-04-19 US disclosed
US-7998987-B2 Inhibitors of c-Met and uses thereof VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-08-16 US disclosed
US-20110034437-A1 ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC. (US) 2011-02-10 US disclosed
US-20110028482-A1 ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC. (US) 2011-02-03 US disclosed
US-20110028478-A1 ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC. (US) 2011-02-03 US disclosed
US-20100273764-A1 INHIBITORS OF PI3 KINASE AND/OR MTOR AMGEN INC. (US) 2010-10-28 US disclosed
US-20100190774-A1 INHIBITORS OF C-MET AND USES THEREOF VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-07-29 US disclosed
US-7728017-B2 Inhibitors of c-Met and uses thereof VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-06-01 US disclosed
US-7435498-B2 Polymer electrolyte membranes crosslinked by nitrile trimerization 3M INNOVATIVE PROPERTIES COMPANY (US) 2008-10-14 US disclosed
US-20070191369-A1 Inhibitors of c-Met and uses thereof VERTEX PHARMACEUTICALS INCORPORATED 2007-08-16 US disclosed